pluri-biotech.com (PLUR) - Long-Term Debt to Capital Coefficient

Pluri - graphic logo of issuer PLUR

A strong team of Israeli placental technology scientists provides the intellectual potential of Pluri Inc. (PLUR). The ratio of long-term loans to equity visualizes the financial dynamics, where the value 0.00 captures the metric level. The business foundation is a modern plant in Israel with an autonomous power supply. However, the lack of recurring revenue due to a focus on clinical trials makes the company dependent on external financing.

pluri-biotech.com (PLUR): Long-Term Debt to Equity from 04/28/2023 to 10/30/2026
Signature product of Pluristem Therapeutics

A fundamental stress test of assets requires an assessment of the financing structure's resilience. Pluri Inc. is currently undergoing a business transformation phase as it develops sales markets for cellular technologies. The long-term debt-to-equity ratio determines the degree of financial leverage and dependence on creditors. By analyzing changes in long-term debt relative to equity, an investor can see the balance between borrowed capital and internal reserves. A low debt load confirms the business's safety during the current period of losses.

Analysis of competing companies

Ascendis Pharma AS - Long-Term Liabilities to Equity|Long-Term Debt to Capital MDGL|CORT (Corcept Therapeutics Corp) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital RYTM (Rhythm Pharmaceuticals)|Long-Term Debt to Capital akerotx.com AKRO|MTSR - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient MLTX (MoonLake Immunotherapeutics AG)|Crinetics Pharma (CRNX) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio NewAmsterdam Pharma Corp|SLNO (Soleno Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital amicusrx.com|Long-Term Debt to Equity Ratio ETNB (89bio)|AGIO (Agios) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Structure Pharma GPCR|MDXG - Long-Term Debt to Equity Ratio|Rezolute, Inc. - Long-Term Debt to Capital|Long-Term Liabilities to Capital lexpharma.com|MBX (MBX Biosciences) - Long-Term Debt to Equity Ratio|ALT: Long-Term Loans to Capital Ratio|AARD (Aardvark Therapeutics Corp) - Long-Term Debt to Capital|Long-Term Debt to Capital Sagimet Biosciences Inc|Long-Term Debt to Capital BIOA|Long-Term Debt to Equity BMEA (biomeafusion.com)|Long-Term Debt to Equity Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. (GUTS) - Long-Term Liabilities to Capital|VTVT - Long-Term Debt to Equity|ATPC: Long-Term Debt to Equity|SYBX: Long-Term Debt to Capital|LPCN - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Matinas BioPharma Holdings, Inc.|Spruce Biosciences Inc. (SPRB) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Galecto Corp (GLTO)|Long-Term Debt to Equity Ratio Carmell Therapeutics CTCX|Long-Term Debt to Equity Lumos Pharma, Inc. LUMO|ONVO (organovo.com) - Long-Term Liabilities to Equity|RDUS - Long-Term Debt to Equity